Company intelligence
Korsana Biosciences
Building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases.
About Korsana Biosciences
Korsana Biosciences is committed to building best-in-class therapeutics with the goal of reducing the burden of neurodegenerative diseases for patients and caregivers. The Company’s lead program, KRSA-028, is a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer’s disease. KRSA-028 leverages Therapeutic Targeting (THETA™), a novel CNS shuttle technology developed in partnership with Paragon Therapeutics and designed to enable dramatically higher drug concentrations in the brain and overcome the limitations of earlier shuttle technologies. In addition, Korsana is advancing a pipeline of innovative therapies for neurodegenerative diseases. For more information, please visit www.korsana.com.
Verified activity
Signals from Korsana Biosciences
2 published signals
Strategy & Corporate Development
Korsana Biosciences completed a merger with Cyclerion Therapeutics to become a publicly traded company.
Reported by Korsana Biosciences
Capital & Finance
Korsana Biosciences closed a $380 million financing round to support its work in the coming years, including through multiple clinical milestones for its lead program KRSA-028.
Reported by Korsana Biosciences